Company intelligence / Profile preview

CardiacSense

Ownership: Private
Employees: ~40
Development stage: Commercial

Overview

Clinical studies have demonstrated the CardiacSense watch achieves 99% sensitivity and 99% specificity in distinguishing atrial fibrillation from normal heart rhythms. The device has received FDA clearance and CE Mark for specific features. It has completed multiple clinical trials at leading medical centers in Israel and the US

Therapeutic areas: PulmonologyCardiovascular
Modalities: Device
Industry: Physiological Monitoring

Partnerships

Significant contracts with healthcare providers internationallynotable $32.4 million deal in India for remote patient monitoring

Beyond the preview

Go deeper on CardiacSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardiacSense.

Explore the full profile